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Abstract
Randomized controlled trials assessing new antimicrobials are frequently designed, performed and analysed by the industry. The author-
ship of these trials is not always transparent, even though authors are expected to be the guarantors of the data presented. Guest
authors may not be able to assume full responsibility for all trial data, and ghost authors are frequently no longer available when the
need to re-analyse trial results or complement published data arises. Academic and clinical contributions during the planning and design
stages of a trial are important. We welcome transparent and appropriate authorship of industry-initiated randomized controlled trials
with both positive and negative results.
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Many of us would welcome a single-dose cure for infections.
In this issue, we publish the results of a randomized con-
trolled trial comparing single-dose extended-release
azithromycin with a 3-day regimen of immediate-release
azithromycin for the treatment of group A b-haemolytic
streptococcal (GABHS) pharyngitis/tonsillitis (Jorgensen, this
issue).
The article has a sole author, who is an employee of Pﬁz-
er, the pharmaceutical company that produces azithromycin,
who planned, conducted and analysed the results of the trial.
Editorial support funded by Pﬁzer is acknowledged, as is the
contribution of three physicians who are not afﬁliated with
the company. We would like to commend the transparency
of the authorship of this manuscript.
In 46 primary publications of industry-sponsored random-
ized controlled trials assessing new antibacterial or antifun-
gal drugs appearing in PubMed during the last year, the
median number of authors per trial was nine (3–25).
Authors afﬁliated with the sponsoring company were pres-
ent in 28 publications (61%), and as ﬁrst or corresponding
author in only nine (20%). Thus, 80% of study guarantors
were academically afﬁliated authors (Table S1). These trials
provide the evidence upon which our practice as infectious
disease clinicians relies: the diseases targeted, the interven-
tions tested, the outcomes assessed, and the results. They
are frequently designed, conducted and analysed by the
company producing a new drug. Unfortunately, the publica-
tions concerning these trials are often authored by academ-
ically afﬁliated authors who did not participate in each
crucial stage of the trial, as required for authorship by the
Uniform Requirements for Manuscripts Submitted to Bio-
medical Journals [1].
Gøtzsche et al. [2] compared the protocol of industry-ini-
tiated trials with the ﬁnal publication submitted to an ethics
committee in Denmark during a 2-year period. The preva-
lence of ghost authorship, deﬁned as the existence of individ-
uals who wrote the trial protocol, performed statistical
analyses or wrote the manuscript and were not listed as
authors of the publication, was 91% (40 of 44 articles;
95% CI 78–98%). The same authors reported their experi-
ence when trying to obtain basic trial data from authors of
randomized controlled trials concerning new antifungals
included in a systematic review [3]. Despite numerous and
creative attempts to contact the authors, only four of 11
responded, and all replied that they no longer had access to
trial data. The editors of the JAMA conducted a questionnaire
survey among corresponding authors in peer-reviewed jour-
nals [4]. The prevalence of honorary authorship, deﬁned as
authors who did not meet authorship criteria, was 14% in
research articles published in the top three US general medi-
cal journals (Annals of Internal Medicine, JAMA, New England
Journal of Medicine) in 1996. Ghost authorship was found in
17% of research articles. No study has previously assessed
the prevalence of guest and ghost authorship in trials assess-
ing new antimicrobials. According to the data above, this
may not be a rare occurrence, although we have absolutely
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no way to distinguish between guest authors and fully quali-
ﬁed authors.
We increasingly realize the need for a guarantor who
has full access to trial data. Accountability and responsibility
are required from authors, to be able to interpret and re-
analyse their data as new evidence regarding outcomes,
adverse events or patient-related risk factors for adverse
outcomes comes to light. Recent examples include the
unsatisfactory efﬁcacy analysis of new antifungals [5,6] or
the analysis of adverse events related to rofexocib [7].
Guidelines concerning good clinical practice should probably
mandate that trial guarantors keep accessible trial data for
a certain period of time after completion of the trial and
publication of its results. Currently, only institutional review
board records are required to be kept for a minimum of
3 years [8]. Conversely, some industry-initiated trials are
never published, and it has been shown that unpublished
data may skew the evidence, as is apparent from published
literature [9,10]. This, again, has not been quantiﬁed sys-
tematically in trials concerning antimicrobials, although this
phenomenon has been shown to exist [11]. The responsi-
bility of academic participants in industry-initiated trials
extends to ensuring that all trial results, both positive and
negative, are published.
Jorgensen and Pﬁzer (this issue) have carefully designed a
trial to establish the non-inferiority of extended-release azi-
thromycin in order to meet FDA approval requirements for
the treatment of GABHS pharyngitis/tonsillitis. Thus, the out-
come of microbiological eradication in the bacteriological
per-protocol population was selected. Optimally, trials
should be planned, designed, analysed and reported by clini-
cians. Using the trial by Jorgensen as an example, a health-
care practitioner participating in the planning might have
commented that a more appropriate comparator than a 3-
day regimen of immediate-relase azithromycin would be a
10-day regimen of penicillin, the current standard of practice
for the treatment of GABHS tonsillitis [12]. At the design
stage, a clinician would probably have wanted to assess clini-
cal outcomes among all patients, not only in the per-proto-
col microbiologically proven population consisting of 70% of
the patients randomized. The randomized population,
patients with clinical signs and symptoms of pharyngitis and a
positive rapid antigen test or culture result, is the patient
population treated in clinical practice. Clinicians should know
how this population fares with the comparative treatment
regimens. Obviously, oversights at the planning and design
stages of a trial cannot be adjusted for later; data that were
not collected are not available. At the reporting stage, a clini-
cian would probably have presented clinical efﬁcacy, in addi-
tion to microbiological efﬁcacy, according to the
susceptibility of the isolates to azithromycin. Other sub-
groups of interest would have been patients with fever and
tonsillar exudates at baseline or those with recurrent infec-
tions in the past. All adverse events could have been pre-
sented in addition to treatment-related adverse events,
which may have been attributed to treatment by the spon-
sor, as this was a placebo-controlled double-blind double-
dummy randomized controlled trial.
Clinicians alone could not have conducted this trial with-
out massive funding. A case has been made for public fund-
ing and oversight of clinical trials [13]. In the extreme, an
independent testing agency, funded by taxes from the phar-
maceutical industry and/or general tax revenue, would
employ scientists to conduct clinical trials. A federal agency
would oversee the process of drug testing. This strategy
would ensure that the appropriate trials are conducted and
appropriate interventions are selected, and would ensure
that all results are fully disclosed to the public as soon as
they are available. It would eliminate the conﬂicts of inter-
est inherent to the situation in which the company market-
ing a drug is responsible for the scientiﬁc appraisal of its
own product. Ultimately, the industry would also beneﬁt
from such a shift, which would allow companies to focus
on the development of drugs prioritized by the scientiﬁc
community, rather than investing most of their resources in
clinical testing.
Although attractive, such a paradigm shift will probably
not occur in the near future. Pending Utopia, we welcome
industry-initiated randomized controlled trials with both
positive and negative results. Manuscripts will be judged on
their scientiﬁc merit and not by the authorship byline, the
number of authors, or their academic prestige. All persons
contributing signiﬁcantly to the planning, design, conduct,
analysis and manuscript drafting should be acknowledged.
The authors should be fully accountable, and should assume
full responsibility for all trial data.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Randomized controlled trials of antibacterial
or antifungal drugs published between July 2007 and August
2008 in PubMed.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the arti-
cle.
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